Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)

NARecruitingINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

July 26, 2027

Study Completion Date

December 5, 2027

Conditions
Persistent Atrial FibrillationCardiac ArrhythmiaCatheter Ablation
Interventions
PROCEDURE

Pulmonary vein isolation

The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.

PROCEDURE

DC Cardioversion

DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.

DEVICE

Implantable loop recorder

The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .

PROCEDURE

Femoral sheath insertion

Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.

Trial Locations (1)

EC1A 7BE

RECRUITING

Barts Heart Centre, London

All Listed Sponsors
lead

Barts & The London NHS Trust

OTHER